In advanced NSCLC, tumor mutational burden (TMB) is a biomarker of immune checkpoint inhibitor (ICI) clinical benefit independent from programmed cell death ligand 1 (PD-L1) expression. The gene discussed is CD274; the disease is neoplasm.